BMS-986525
/ BMS
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
January 09, 2026
A Study to Assess the Safety and Tolerability of BMS-986525 Alone and in Combination With Nivolumab in Participants With Relapsed/Refractory Small Cell Lung Cancer
(clinicaltrials.gov)
- P1/2 | N=240 | Not yet recruiting | Sponsor: Bristol-Myers Squibb
Monotherapy • New P1/2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
1 to 1
Of
1
Go to page
1